On May 8, AstraZeneca's new small molecule drug plant in Wuxi officially started construction. The new plant has a total investment of US$475 million and covers an area of about 30,000 square meters. It will be equipped with two sets of cutting-edge tablet continuous manufacturing process equipment and seven sustainable drug packaging production lines. It will mainly produce AstraZeneca's innovative cardiovascular drugs in its pipeline and is expected to be put into production in the fourth quarter of 2028. This is a further deepening of AstraZeneca's supply chain layout in China after the completion of the main building of the first phase of the Qingdao Inhalation Aerosol Production and Supply Base last month.